Cytek BioSciences Inc Stock News

Cytek Biosciences offers a full-spectrum cytometry platform. This means they provide instruments, reagents, services, and cloud software. Their main value proposition is to allow clients to achieve higher-parameter cell analysis than conventional flow systems. Its core product portfolio centers around Aurora, Northern Lights, Aurora CS, and Aurora Evo. Each targets a different price-performance...

FREMONT, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced its inclusion on TIME's 2026 list of America's Growth Leaders.

FREMONT, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) announced today that its Cytek ® Muse ® Micro cell analyzer has been named Drug Discovery Solution of the Year in the 2025 BioTech Breakthrough Awards.

FREMONT, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences.

Cytek Biosciences, Inc. ( CTKB ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Paul Goodson Wenbin Jiang - President, CEO & Chairman of the Board William McCombe - Chief Financial Officer Conference Call Participants David Westenberg - Piper Sandler & Co., Research Division Brendan Smith - TD Cowen, Research Division Harrison Parsons - Stephens Inc., Research Division ...

FREMONT, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2025.

FREMONT, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amid the reduction of various government grant programs and global economic challenges that have tightened research funding, Cytek Biosciences, Inc. (Nasdaq: CTKB) is taking steps to ensure critical scientific research can continue.

FREMONT, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the third quarter 2025 after market close on Wednesday, November 5, 2025. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its ...